Clinical Trials Logo

Head and Neck Cancer Metastatic clinical trials

View clinical trials related to Head and Neck Cancer Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05582590 Not yet recruiting - Clinical trials for Head and Neck Cancer

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

Start date: March 31, 2025
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers. Patients must have received at least one prior standard treatment regimen consisting of systemic immunotherapy and/or chemotherapy. The investigative agent is an autologous adoptive T-cell product derived from the patient's endogenous cytolytic T cells that are directed toward HPV-16 E6/E7, HPV-18 E6/E7 antigens, and a tumor-associated antigen (Survivin) by ex vivo exposure to an artificial antigen presenting cell to which HLA-A2 antigen-peptides have been fit within the pocket of an MHC class 1 molecule. Patients must express HLA-A*0201.

NCT ID: NCT03993353 Recruiting - Cancer Clinical Trials

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Start date: April 7, 2020
Phase: Phase 2
Study type: Interventional

This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.

NCT ID: NCT03878979 Completed - Clinical trials for Head and Neck Cancer

Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN

Start date: July 8, 2019
Phase: Phase 2
Study type: Interventional

Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN).

NCT ID: NCT03265080 Terminated - Metastatic Melanoma Clinical Trials

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

NEO
Start date: March 28, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, multicenter study of ADXS-NEO administered alone and in combination with pembrolizumab in participants with select advanced or metastatic solid tumors. This study will be performed in 2 phases, a safety phase (Part A and Part B) and an efficacy phase (Part C).

NCT ID: NCT02474368 Active, not recruiting - Clinical trials for Recurrent Head and Neck Carcinoma

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Start date: November 2015
Phase: Phase 1
Study type: Interventional

This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.